Please provide your email address to receive an email when new articles are posted on . Lirentelimab was safe and effective in the long-term treatment of patients with eosinophilic gastritis and/or ...
45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic ...
SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results